Urologic Imaging

Should You Order CTU for Microhematuria with Risk Factors? An ACR-Guided Workflow

·
Should You Order CTU for Microhematuria with Risk Factors? An ACR-Guided Workflow

A 65-year-old male with a 30-pack-year smoking history is in your clinic for a routine physical. A urinalysis, performed for screening, reveals 8 RBCs/hpf on microscopy. He is entirely asymptomatic, and repeat urinalysis confirms the finding. You have already ruled out transient causes like infection or recent strenuous activity. Now, you must decide on the appropriate initial imaging to evaluate for an underlying urologic malignancy. This article provides a detailed clinical workflow for this specific scenario: asymptomatic microhematuria in a patient with risk factors. For this presentation, the American College of Radiology (ACR) rates CT Urography (CTU) without and with IV contrast as Usually appropriate.

Who Fits This Clinical Scenario for Microhematuria Imaging?

This guidance applies to a well-defined patient population. The central finding is asymptomatic microscopic hematuria, typically defined as three or more red blood cells per high-power field (RBCs/hpf) on a properly collected urine specimen, in the absence of an obvious benign cause.

Inclusion Criteria:
The key differentiator for this workflow is the presence of one or more risk factors for urothelial malignancy. These include:

  • Age greater than 35 years
  • History of smoking (current or former)
  • Male sex
  • Occupational exposure to chemicals or dyes (e.g., benzenes, aromatic amines)
  • History of gross hematuria
  • Prior pelvic irradiation
  • Chronic cyclophosphamide exposure
  • History of chronic urinary tract infections

Exclusion Criteria (These Patients Require a Different Workflow):
This workflow is not appropriate if the patient has:

  • No risk factors: Younger patients without risk factors may undergo a different evaluation, often starting with less invasive imaging or observation.
  • Gross hematuria: The visible presence of blood in the urine is a distinct and more urgent clinical scenario that mandates a prompt and thorough evaluation.
  • A clear benign cause: This includes confirmed urinary tract infection, recent vigorous exercise, or menstruation. These conditions should be addressed and the urinalysis repeated before proceeding with an imaging workup for malignancy.
  • Known renal parenchymal disease: Patients with established glomerulonephritis or other nephrologic conditions are managed by nephrology, and the workup focuses on renal function and serologies rather than initial anatomic imaging for cancer.

What Diagnoses Are You Working Up in Patients with Risk Factors for Microhematuria?

In this specific scenario, the primary goal of imaging is to detect or exclude malignancy of the urinary tract. While many causes of microhematuria are benign, the presence of risk factors elevates the index of suspicion for serious pathology, guiding the choice of a high-sensitivity imaging study.

Urothelial Carcinoma (UC)
This is the most significant concern. Urothelial carcinoma, also known as transitional cell carcinoma (TCC), can arise anywhere along the lining of the urinary tract, from the renal calyces and pelvis (upper tract) down through the ureters and into the bladder (lower tract). Upper tract tumors are often small, subtle, and may only present as a filling defect or focal wall thickening within the collecting system. The imaging workup must be optimized to visualize this entire urothelial surface.

Renal Cell Carcinoma (RCC)
While many renal masses are found incidentally, microhematuria can be a presenting sign, particularly if the tumor invades the collecting system. Small renal masses are a key target for detection, as their early identification and treatment can be curative. The imaging study must be able to characterize renal parenchymal lesions effectively.

Urolithiasis (Kidney Stones)
Urinary stones are a very common cause of both microscopic and gross hematuria. While typically benign, they can cause significant symptoms and complications like obstruction. A comprehensive imaging evaluation should be able to definitively identify stones of all compositions and locations.

Benign Structural Abnormalities
Less common but important considerations include benign conditions like medullary sponge kidney, papillary necrosis, or vascular malformations (e.g., arteriovenous malformations) that can cause bleeding. A high-quality imaging study can often identify or suggest these alternative diagnoses.

Why Is CT Urography the Recommended Study for Microhematuria with Risk Factors?

The American College of Radiology (ACR) designates CTU without and with IV contrast as Usually appropriate for this clinical scenario. This recommendation is based on the modality’s unique ability to provide a comprehensive evaluation of the entire urinary tract—kidneys, collecting systems, ureters, and bladder—in a single examination.

A CTU is a specialized, multi-phase protocol designed to answer the specific clinical questions posed by hematuria:

  • Non-contrast Phase: This initial scan is the gold standard for detecting urolithiasis (kidney stones). It provides a high-contrast view of calcifications anywhere in the urinary tract, which might be obscured by intravenous contrast.
  • Nephrographic Phase: Acquired approximately 70-100 seconds after IV contrast injection, this phase provides optimal enhancement of the renal parenchyma. It is the most sensitive phase for detecting and characterizing solid renal masses, such as renal cell carcinoma.
  • Excretory (Delayed) Phase: Acquired 5 to 15 minutes after contrast injection, this is the defining phase of a CTU. The contrast has been filtered by the kidneys and is now opacifying the renal calyces, pelvis, ureters, and bladder. This phase distends the urothelial-lined structures, allowing for the detection of filling defects, wall thickening, or strictures that suggest urothelial carcinoma.

This multi-phasic approach provides a complete anatomic and functional overview that is essential in a high-risk patient.

Why are alternative studies rated lower for this specific scenario?

  • US kidneys and bladder retroperitoneal: Rated May be appropriate. Ultrasound is excellent for evaluating the renal parenchyma for masses or hydronephrosis and assessing the bladder for larger tumors. However, it is limited by its inability to visualize the majority of the ureters and its lower sensitivity for small, flat urothelial lesions. In a patient with risk factors for malignancy, its failure to evaluate the entire urothelium makes it an incomplete study.
  • CT abdomen and pelvis with IV contrast (single phase): Rated Usually not appropriate. This is a common pitfall. A standard single-phase portal venous CT is not a CTU. It lacks the essential non-contrast phase for stone detection and the critical excretory phase for urothelial evaluation. Ordering this study is insufficient for a complete hematuria workup and may lead to missed diagnoses.

The primary trade-off with CTU is the radiation dose, which is rated as ☢☢☢☢ (10-30 mSv). However, in this patient population, the diagnostic benefit of definitively evaluating for a potentially life-threatening malignancy is considered to outweigh the radiation risk.

What’s Next After CTU without and with IV contrast? Downstream Workflow

The results of the CT Urogram will guide the subsequent clinical pathway. The next steps are determined by whether the findings are positive, negative, or indeterminate.

  • If the CTU is positive for a suspicious mass:
  • Renal Mass: A finding suspicious for RCC will typically lead to a urology consultation for surgical planning (e.g., partial or radical nephrectomy) or biopsy, depending on the lesion’s characteristics and patient comorbidities.
  • Upper Tract Urothelial Lesion: A filling defect or thickening in the renal pelvis or ureter requires urgent urologic referral for ureteroscopy with biopsy to obtain a tissue diagnosis.
  • Bladder Lesion: While cystoscopy is the gold standard for bladder evaluation, a lesion seen on CTU also requires urgent urology referral for cystoscopy and transurethral resection of bladder tumor (TURBT).
  • If the CTU is negative:

A negative CTU provides strong evidence against significant upper tract pathology. However, it does not complete the hematuria evaluation. The next essential step is cystoscopy to directly visualize the bladder lining, as small or flat bladder lesions (carcinoma in situ) can be missed even on high-quality CTU. If both the comprehensive upper tract imaging (CTU) and lower tract evaluation (cystoscopy) are negative, the patient can typically be reassured and monitored.

  • If the CTU is indeterminate:

Occasionally, a finding like focal urothelial thickening may be equivocal. In these cases, the next step may be a direct-look procedure like ureteroscopy to resolve the ambiguity. Alternatively, if the finding is low-risk, short-term follow-up imaging with CTU or MRU may be considered.

Pitfalls to Avoid (and When to Get Help)

Navigating the workup for microhematuria requires careful attention to detail to avoid common errors that can delay diagnosis or lead to unnecessary testing.

1. Incomplete Workup: A negative CTU is not the end of the evaluation. Failing to proceed with cystoscopy after a negative upper tract study is a significant pitfall that can miss bladder cancer.
2. Ordering the Wrong CT: Do not order a “CT Abdomen/Pelvis with contrast” and assume it is a CTU. You must specifically order a “CT Urogram” or “CT for Hematuria” to ensure the multi-phasic protocol is performed.
3. Ignoring Patient Factors: For patients with contraindications to iodinated contrast (e.g., severe allergy, poor renal function), CTU is not appropriate. In these cases, Magnetic Resonance Urography (MRU) without and with IV contrast, rated May be appropriate, becomes the preferred alternative for upper tract imaging.
4. Over-imaging Low-Risk Patients: Applying this aggressive workup to young patients without risk factors is generally not indicated and leads to unnecessary radiation exposure and cost.

If you encounter a complex renal mass, an indeterminate urothelial finding, or a patient with conflicting results, a consultation with a urologist or a subspecialty-trained abdominal radiologist is the appropriate next step.

Related ACR Topics and Tools

For a comprehensive overview of all clinical variants related to hematuria, from pregnant patients to those with gross hematuria, please see our parent guide. For tools to help you implement these recommendations, the resources below provide direct access to criteria, protocols, and dose information.

Frequently Asked Questions

Why is CT Urography preferred over MR Urography for most patients with risk factors?

CT Urography (CTU) is generally preferred because it is faster, more widely available, and superior for detecting urolithiasis (kidney stones), which is a common cause of hematuria. While MR Urography (MRU) is an excellent alternative that avoids ionizing radiation, it is typically reserved for patients with a contraindication to iodinated contrast (like severe allergy or poor renal function) or for problem-solving in specific cases.

My patient has risk factors but their creatinine is elevated. Can I still order a CTU?

This requires careful consideration. The risk of contrast-induced nephropathy (CIN) must be weighed against the risk of missing a malignancy. For patients with moderate chronic kidney disease, pre-procedure hydration may be sufficient. For those with severe renal impairment (e.g., eGFR < 30 mL/min/1.73m²), CTU with contrast is often contraindicated. In these cases, MR Urography without and with gadolinium-based contrast (if eGFR is adequate for that agent) or a combination of non-contrast CT and retrograde pyelography may be considered in consultation with urology and radiology.

If the CTU is negative, is any further workup needed?

Yes. A complete evaluation for hematuria in a high-risk patient requires assessment of both the upper tracts (kidneys and ureters) and the lower tract (bladder). A negative CTU effectively rules out significant upper tract pathology, but the evaluation is incomplete without a cystoscopy to directly visualize the bladder mucosa. Small, flat lesions like carcinoma in situ (CIS) of the bladder can be missed on CTU.

What is the difference between a standard ‘CT Abdomen/Pelvis with contrast’ and a ‘CT Urogram’?

A standard CT Abdomen/Pelvis with IV contrast is typically a single-phase study acquired in the portal venous phase. It is optimized for evaluating solid organs like the liver and spleen but is not designed to evaluate the urinary collecting system. A CT Urogram is a dedicated, multi-phase protocol that includes non-contrast, nephrographic, and, most importantly, delayed excretory phases. The excretory phase is essential for opacifying the ureters and bladder to detect urothelial tumors, which would be missed on a standard single-phase CT.

Does a history of a single episode of gross hematuria years ago count as a risk factor?

Yes. Any history of gross hematuria, even a single remote episode, is considered a significant risk factor for underlying urologic malignancy and warrants a full evaluation, even if the current presentation is only microhematuria. The patient should be worked up according to the high-risk pathway.

Reviewed by Pouyan Golshani, MD, Interventional Radiologist — May 29, 2026